Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05591131 | Genetic Testing in African Americans(GTM-I) | active not recruiting | N/A | 21 | Augusta UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06082765 | Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood | recruiting | — | 10,000 | Zhongnan HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06832397 |
| Detection of Peritoneal Metastases by Diagnostic LAparoscopy in Patients With Locally Advanced Cervical Carcinoma(SOLAR) |
| not yet recruiting |
| — |
| 120 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER |
| 1 |
| Feb 18, 2025 |
| clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04057924 | Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN(SUIVICIN) | recruiting | — | 200 | University Hospital, BordeauxOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06677242 | Serous Endometrial Intraepithelial Carcinoma (SEIC): Prospective Registration Study(SEIC) | not yet recruiting | — | 100 | Erasmus Medical CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06489795 | German-funded Laparoscopic Approach to Cervical Cancer(G-LACC) | recruiting | N/A | 756 | Hannover Medical SchoolOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06805019 | Construction of a Model for the Differential Diagnosis of SArcoma/myoma Based on the RAdiomics Features: Single-center Observational Study(SARA) | recruiting | — | 176 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06800391 | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients(REVERSE) | recruiting | Phase 2 | 31 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800612 | Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers | recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800677 | Methylated Biomarkers Predictive of Endometrial Cancer Risk(BioMEC) | active not recruiting | — | 200 | University of ManchesterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04859530 | Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier | recruiting | N/A | 5,886 | Prof. Patrick PetignatOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06304610 | Hospital-based Validation of the New ELEVATE Screening Tool(ELEVATE-Pilot) | not yet recruiting | N/A | 200 | University Hospital, GhentOTHER | 2 | Jan 27, 2025 | clinicaltrials |
| NCT06392997 | Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology(GynRNA) | recruiting | — | 2,500 | ZIWIGINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05909111 | MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos Therapy: Feasibility Study(Ethos Col) | recruiting | N/A | 15 | Recherche cliniqueOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06776055 | Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women | active not recruiting | — | 5,372 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04061967 | Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer. | recruiting | N/A | 20,000 | Karolinska InstitutetOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774209 | Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06307886 | Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With and Without Uterine Manipulator | recruiting | — | 108 | Gaziosmanpasa Research and Education HospitalOTHER_GOV | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06584032 | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer | recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | not yet recruiting | Phase 1 | 90 | Anhui Provincial HospitalOTHER_GOV | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06759480 | Study of Laparoscopic Radical Hysterectomy Based on Space Anatomy in Patients With IB3 and IIA2 Cervical Cancer | not yet recruiting | — | 500 | International Peace Maternity and Child Health HospitalOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | enrolling by invitation | Phase 2 / Phase 3 | 510 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745427 | A Multi-center Prospective Study on the Oncological and Reproductive Outcomes and Quality of Life in Young Woman After Fertility-sparing Treatment of Endometrial Cancer and Endometrial Intraepithelial Hyperplasia(PreFerEC/EIN) | not yet recruiting | — | 100 | Region StockholmOTHER_GOV | 0 | Dec 20, 2024 | clinicaltrials |
| NCT06649838 | Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions | not yet recruiting | — | 60 | Peking Union Medical College HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06737640 | Evaluation of Clinical and Molecular Biomarkers in Immunotherapy Treatment in Gynecologic Cancer(Immuno-Gyn) | not yet recruiting | — | 90 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02642471 | Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010) | active not recruiting | N/A | 1,080 | Sun Yat-sen UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05855941 | Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)(PRODIGYN) | recruiting | — | 120 | Region VästerbottenOTHER_GOV | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06082882 | Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2(SEMM2) | active not recruiting | N/A | 8,000 | The University of Texas Health Science Center, HoustonOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06726291 | Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer(NOEME) | recruiting | Phase 4 | 84 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05655260 | PErsonalized TReatment for Endometrial Carcinoma(PETREC) | recruiting | N/A | 300 | University of HelsinkiOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer(INTERLACE) | active not recruiting | Phase 3 | 500 | University College, LondonOTHER | 5 | Dec 5, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06603506 | Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study(PENDOR) | recruiting | — | 16 | Centre Francois BaclesseOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06705322 | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. | not yet recruiting | Phase 2 | 79 | Fudan UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT06692166 | A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 420 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06697054 | Sentinel Lymph Node (SLN) Mapping with Charcoal Carbon Dye in Early Stage Cervical Cancer(SLN) | active not recruiting | N/A | 60 | Istanbul UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 21, 2025source: clinicaltrials